Exercise dose and quality of life: a randomized controlled trial

Abstract

Background: Improved quality of life (QOL) is a purported benefit of exercise, but few randomized controlled trials and no dose-response trials have been conducted to examine this assertion.

Methods: The effect of 50%, 100%, and 150% of the physical activity recommendation on QOL was examined in a 6-month randomized controlled trial. Participants were 430 sedentary postmenopausal women (body mass index range, 25.0-43.0 [calculated as weight in kilograms divided by height in meters squared]) with elevated systolic blood pressure randomized to a nonexercise control group (n = 92) or 1 of 3 exercise groups: exercise energy expenditure of 4 (n = 147), 8 (n = 96), or 12 (n = 95) kilocalories per kilogram of body weight per week. Eight aspects of physical and mental QOL were measured at baseline and month 6 with the use of the Medical Outcomes Study 36-Item Short Form Health Survey.

Results: Change in all mental and physical aspects of QOL, except bodily pain, was dose dependent (trend analyses were significant, and exercise dose was a significant predictor of QOL change; P < .05). Higher doses of exercise were associated with larger improvements in mental and physical aspects of QOL. Controlling for weight change did not attenuate the exercise-QOL association.

Conclusion: Exercise-induced QOL improvements were dose dependent and independent of weight change.

Trial registration: ClinicalTrials.gov NCT00011193.

Figures

Figure 1

CONSORT diagram describing recruitment and retention of participants. *Baseline values were carried forward if follow-up QOL scores were missing.

Figure 2

Mean (± SD) baseline SF-36 scores for the DREW sample and the national mean for the United States. The mean QOL scores for the DREW sample differed from the national mean by only 0.02 to 0.22 standard deviation units, which are considered differences of small magnitude .

Figure 3

Mean change (Least-squares means ± 95% confidence interval) on SF-36 measures across the control and exercise groups. The dose-response relations between exercise dose and change in QOL were evaluated with regression analysis to test for trends in QOL change across groups. Significant trends were found for all QOL scales (all p-values

Figure 4

Change in SF-36 scores across the exercise groups was examined for two subgroups of participants: 1) those who lost weight vs. 2) those who maintained or gained weight, using analysis of covariance (ANCOVA) with baseline age, antidepressant use, employment status, ethnicity, marital status, and smoking status as covariates. Mean change (Least-squares means ± 95% confidence interval) on SF-36 scales across the control and exercise groups for participants who did and did not lose weight are depicted. The results from the ANCOVAs follow: PF, F(3, 416) = 0.12, p=0.95; RP, F(3, 416) = 1.00, p=0.39; BP, F(3, 416) = 1.41, p=0.24; GH, F(3, 416) = 0.28, p=0.84; MH (3, 416) = 0.18, p=0.91; RE, F(3, 416) = 2.41, p=0.07; SF, F(3, 416) = 0.87, p=0.46; and VT, F(3, 416) = 0.11, p=0.95. These non-significant interactions indicate that the pattern of change in each of the SF-36 measures across the exercise groups was similar for those who did and did not lose weight.